Purpose Arginine vasopressin (AVP) may be involved in metabolic syndrome (MetS) by altering liver glycogenolysis, insulin and glucagon secretion, and pituitary ACTH release. Moreover, AVP stimulates the expression of 11β-hydroxysteroiddehydrogenase-type 2 (11β-HSD2) in mineralocorticosteroid cells. We explored whether apparent 11β-HSD2 activity, estimated using urinary cortisol-to-cortisone ratio, modulates the association between plasma copeptin, as AVP surrogate, and insulin resistance/MetS in the general adult population. Methods This was a multicentric, family-based, cross-sectional sample of 1089 subjects, aged 18-90 years, 47% men, 13.4% MetS, in Switzerland. Mixed multivariable linear and logistic regression models were built to investigate the association of insulin resistance (HOMA-IR)/fasting glucose and MetS/Type 2 Diabetes with copeptin, while considering potential confounders or effect modifiers into account. Stratified results by age and 11β-HSD2 activity were presented as appropriate. Results Plasma copeptin was higher in men [median 5.2, IQR (3.7-7.8) pmol/L] than in women [median 3.0, IQR (2.2-4.3) pmol/L], P < 0.0001. HOMA-IR was positively associated with copeptin after full adjustment if 11β-HSD2 activity was high [β (95% CI) = 0.32 (0.17-0.46), P < 0.001] or if age was high [β (95% CI) = 0.34 (0.20-0.48), P < 0.001], but not if either 11β-HSD2 activity or age was low. There was a positive association of type 2 diabetes with copeptin [OR (95% CI) = 2.07 (1.10-3.89), P = 0.024), but not for MetS (OR (95% CI) = 1.12 (0.74-1.69), P = 0.605), after full adjustment. Conclusions Our data suggest that age and apparent 11β-HSD2 activity modulate the association of copeptin with insulin resistance at the population level but not MeTS or diabetes. Further research is needed to corroborate these results and to understand the mechanisms underlying these findings.
Introduction
Animal and human studies have suggested that the arginine vasopressin (AVP) system might be implicated in glucose homeostasis, insulin resistance and lipid metabolism [1] [2] [3] [4] [5] .
Since the changes in plasma AVP are very rapid, copeptin has been proposed as a reliable surrogate for AVP activity [6, 7] . Copeptin is the glycopeptide comprising the C-terminal part of the AVP prohormone. Copeptin correlates with AVP levels in plasma and seems to share similar functions [6, 8] . Previous studies have shown that high copeptin levels were associated with incident diabetes [2, 4, 9] , insulin resistance, and distinct components of MetS or MetS itself [3, 5] , mainly in the adult or elderly population. A recent study did not find any association between copeptin levels and insulin resistance in children, but found a positive association between copeptin levels and 24-h urinary free cortisol levels in obese children [10] .
In vitro studies have shown that AVP stimulates the expression of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in human mineralocorticosteroid target cells acting through the AVP V2 receptor [11] . The enzyme 11β-HSD2 is largely expressed in mineralocorticoid target tissues 1 3 (kidney and large bowel) and inactivates cortisol to cortisone [12] [13] [14] . This is an important mechanism to protect the mineracolocorticoid receptor from glucocorticoid excess, since cortisol, like aldosterone, can bind and activate the mineralocorticoid receptor [15] . By contrast, 11β-HSD type 1 (11β-HSD1) is expressed in liver, adipose tissue, muscle and bone, and is able to regenerate cortisol from cortisone. The study of these enzymatic activities is relevant, since local tissue cortisol metabolism seems to be implicated in the pathogenesis of obesity and insulin resistance [12] [13] [14] . As already known, high cortisol levels increase glycogenolysis, gluconeogenesis, insulin resistance, free fatty acids levels, and visceral obesity; thereby increasing the risk of type 2 diabetes (T2D) and MetS [16] . However, obese individuals may present with normal systemic cortisol levels [17] . A recent review shows that inhibition of 11β-HSD1 can be a potential therapeutic benefit to patients with T2D [18] , suggesting that 11β-HSD1 activity may have a role in regulating glycaemia and cardiometabolic risk [19, 20] . An increased activity of 11β-HSD1 is reported in visceral adipose tissue of obese subjects, leading to increased visceral adipose fat mass [21] . In a rat model of obesity, 11β-HSD2 is overexpressed in adipose tissue, suggesting a potential role of this enzyme activity in preventing fat accumulation in adipose tissue [22] . In addition, it has been shown that, in extremely obese subjects, 11β-HSD2 activity is negatively associated with insulin sensitivity [21] .
Taking into account these findings, and previous data relating the association of copeptin with metabolic outcomes, we hypothesized that 11β-HSD2 activity could have an impact on the association between copeptin and metabolic outcomes, and eventually modify this association. This could be of particular relevance to better understand the physiopathology of glucocorticoids and the development of metabolic outcomes at the population level. It could also be interesting in terms of pharmacotherapy. Indeed, nowadays drugs targeting AVP receptors are available; if treatment response happens to differ across 11β-HSD2 activity levels, we could personalize treatment and identify patients susceptible to have different response or even be resistant.
In this study, we analyzed the association of copeptin with insulin resistance and MetS in a Swiss multicentric population-based study and explored whether apparent levels of 11β-HSD2 activity modulates this association. We also aimed to confirm the relationship between copeptin levels and fasting glucose and T2D.
Subjects
Participants were selected from the Swiss Kidney Project on Genes in Hypertension (SKIPOGH study), which is a family and population-based cross-sectional study examining the genetic determinants of blood pressure. SKIPOGH is nested in the European Project on Genes in Hypertension and employs the same validated protocol [23] . Detailed description of the methodology was provided elsewhere [24] . Briefly, 1128 participants were recruited from 2009 to 2013 in two regions (Bern and Geneva) and one city (Lausanne). Inclusion criteria for the participants were the following: having a minimum age of 18 years; being of European ancestry (defined as having both parents and grandparents born in a restricted list of countries); having at least one and ideally three first-degree family members willing to participate; and (4) providing a written informed consent. Pregnant or breastfeeding women were not included. Participants were selected randomly using different strategies in the three centers with a participant rate of 25.6%. The SKIPOGH study followed all the instructions of the Declaration of Helsinki and was approved by the Ethics committee of each participating university hospital.
Materials and methods
Participants filled in at home a standardized questionnaire focused on lifestyle habits, medical and drug history. Daily consumption of fruits and vegetables was self-reported through the questionnaire as a continuous variable from none to eight pieces per day. Low consumption of fruits and vegetables was defined as the lowest quintile (from none to four pieces per day). Current alcohol consumption and smoking were self-reported and considered as dichotomous variables. Socioeconomic status was assessed on the basis of occupation and education information provided by the questionnaire. Regarding education, subjects were classified into one of four categories: graded in University; higher secondary school; lower secondary school; primary school or lower. Occupational status was based on questions related to their current job and actual work tasks. Individuals were classified into one of four categories: managers; lower level managers; skilled workers or self-employed; skilled or unskilled physical workers. The socioeconomic score was calculated as the sum of the education and occupation categories: the lower the score the higher the socioeconomic status. Low socioeconomic score was defined as the highest quintile of the socioeconomic score. Physical activity was self-reported and was measured as a scale from 1 to 10 of grade of physical efforts. Low physical activity was considered equal or less than five.
All participants went to a study visit in the morning after an overnight fast where blood samples and anthropometric measurements were taken. Usual blood measurements (lipid profile, glucose, insulin) were done locally using standard clinical laboratory methods. Copeptin was measured centrally on plasma samples using a previously described sandwich immunoluminometric assay [23] . We measured insulin by using ECLIA method by COBAS Roche, for Lausanne data, immunochemiluminescenceby Siemens for Geneva data, and by ElectroChemiLumineszenzImmunoAssay (ECLIA) Roche, for Bern Data. Interlaboratory Lins's correlation coefficient was excellent [r = 0.89 (95% CI: 0.75-0.95)]. HOMA-IR was used as a surrogate for insulin resistance and was calculated as follows: HOMA-IR = (FPI × FPG)/22.5; where FPI is fasting plasma insulin concentration (mU/l) and FPG is fasting plasma glucose (mmol/L) [25] . Subjects were classified as having MetS according to the National Cholesterol Education Program Adult Treatment Panel III criteria [26] . Briefly, they were assigned as having MetS if they had three or more of the following characteristics: waist circumference greater than 102 cm in men and greater than 88 cm in women; fasting plasma glucose concentration ≥ 6.1 mmol/L or treatment for diabetes; HDL < 1.0 mmol/L in men and < 1.3 mmol/L in women; triglycerides (TG) ≥ 1.7 mmol/L or use of anti-lipid medications; and systolic blood pressure (BP) ≥ 130 mm Hg and/or diastolic BP ≥ 85 mm Hg or use of antihypertensive medication. Diabetes was defined as present if reported, treated, or fasting glycemia was ≥ 7 mmol/L.
Body weight and height were measured using precision electronic scales (Seca, Hamburg, Germany). Participants were provided oral and written instruction on how to collect 24-h urine, using two separate bottles for day and night urine. Daytime corresponds to the participants' urine collection starting with the second urine sample in the morning until the last one before bedtime. Blood pressure was measured using a validated sphygmomanometer in seated position after a 10-min rest. The mean of the last four measurements was recorded.
Gas chromatography-mass spectrometry (GC-MS) of steroid metabolites
Urinary steroid metabolites were extracted and analyzed by GC-MS according to the method described by Shackleton [27] . Urinary excretion of glucocorticoid metabolites and sex steroid hormones (testosterone and 17-β estradiol) was measured. Total glucocorticoid metabolites were defined as the sum of cortisol (F), cortisone (E), tetrahydrocortisol (THF), 5α-tetrahydrocortisol (5α-THF), tetrahydrocortison (THE), α-cortolone, β-cortolone, α-, and β-cortol [28] . Urinary F-to-E ratio (F/E) was used as a measure of 11β-HSD2 activity [12] .
Statistical analysis STATA 13 .0 software (StataCorp, College Station, TX) was used for all the analyses. Complete data on components of MetS, copeptin, corticosteroids, covariates and potential confounders were available for 1089 (96.5%) individuals. Data were expressed as mean ± SD or median ± IQR (25th percentile-75th percentile) as appropriate; and as numbers and percentages (%) if categorical variables. Fasting insulin, HOMA-IR, copeptin, serum triglycerides and urinary steroid hormone metabolites measures were log-transformed since their distribution was skewed. Categorical variables were evaluated using χ 2 test. Non parametric Mann-Whitney U test or Student's t test was used for the comparison of continuous variables. Statistical significance was considered for a two-sided P < 0.05, except for interaction tests where the threshold of 0.10 was considered as statistically significant. Taking familial correlations into account, we built different multivariable mixed linear regression models to determine the independent association of copeptin, as the independent variable of interest, with insulin resistance (measured as HOMA-IR) and fasting glucose (as the dependent variables). In the first model, we adjusted for age, sex and center. In the second model, we additionally adjusted for socioeconomic status, intake of fruits and vegetables [3] , physical activity levels, consumption of alcohol and smoking status. In the third model, we added sex steroids (daytime testosterone and estradiol urinary excretions).
We followed the same procedure to investigate the independent association of copeptin with MetS and T2D, using mixed logistic multivariable regression models.
We tested the interaction of copeptin with sex and age for their effects on HOMA-IR, fasting glucose and MetS. The number of T2D participants was too small to run stratified analyses for this outcome. To explore the potential modifying effect of daytime 11β-HSD2 activity on the relationship between copeptin and metabolic traits, we tested the interaction of copeptin with 11β-HSD2 activity (measured as daytime urinary cortisol-to-cortisone ratio [12] ) for their effects on HOMA-IR, fasting glucose and MetS. We used a likelihood ratio test and compared the model with the interaction variable to the model without it. When an interaction with copeptin was present, we conducted stratified analyses using the median value (respectively, for 11β-HSD2 activity and age) as a cut-off. As the increase in urinary F/E ratio indicates a reduced 11β-HSD2 activity [12] , the highest category of urinary F/E ratio represents a reduced 11β-HSD2 activity and the lowest an increased 11β-HSD2 activity.
We used the margin function in STATA to generate a figure of the predicted probability of insulin resistance (HOMA-IR) at each quartiles of log-transformed copeptin, adjusted for age, sex and center. This was done with stratification for 11β-HSD2 activity.
Sensitivity analyses were done by adding daytime urine flow rate and 24 h urinary creatinine excretion as covariates in the models. Similarly, we added CRP and eGFR as covariates. Further sensitivity analyses were done after excluding participants with a pharmacological treatment such as antihypertensive, lipid-lowering and/or anti-diabetic drugs.
Results

Characteristics according to sex, 11β-HSD2 activity and age
We analyzed 1089 subjects with complete data, from which 47% were men. Baseline characteristics of the population are shown in Supplementary Table 1, stratified by sex although there was no interaction between copeptin and sex. T2D and MetS were present in 4.5 and 13.4% of the participants. Men had higher BMI, blood pressure, glucose, insulin and triglyceride levels than women. They also had higher copeptin levels, urinary daytime glucocorticoid, cortisone and cortisol excretion (see Supplementary Figure 1 ). The prevalence of T2D was higher in men, as compared to women. Insulin resistance, estimated with HOMA-IR, was higher in men. Prevalence of MetS, as well as the estimated 11β-HSD2 enzyme activity, was similar in both men and women.
As we found an interaction between copeptin and 11β-HSD2 activity (P = 0.057) with respect to HOMA-IR, we then presented characteristics according to 11β-HSD2 activity strata (Table 1 ). To note, there was no interaction for fasting glucose (P = 0.456) or MetS (P = 0.284). If 11β-HSD2 enzymatic activity was highest, participants were less overweight, had lower blood pressure, and were less insulin resistant, as compared to participants belonging to the lowest apparent 11β-HSD2 enzymatic activity strata. Plasma copeptin levels were lower in the strata of highest 11β-HSD2 enzymatic activity as compared to the lowest activity. The total urinary excretion of glucocorticoid metabolites was higher in the strata of the highest enzymatic activity. As expected, cortisol excretion was lower in the strata of the highest enzymatic activity, whereas cortisone excretion was higher. There were no differences in age or sex distribution. We also found a significant interaction between copeptin and age for their effects on HOMA-IR (P < 0.001). This interaction was also present for fasting glucose (P interaction < 0.001), but not for MetS (P interaction = 0.778). When comparing characteristics by age strata, we found that older subjects were less smokers, but more overweight, with higher blood pressure and more insulin resistance that youngest subjects (see Table 2 ). Copeptin levels and apparent 11β-HSD2 enzymatic activity were similar in both age strata. Cortisol excretion was slightly lower in older participants than in younger ones.
Correlations between copeptin and steroids
When looking at the univariate association of copeptin and steroids, we found a positive correlation between copeptin and urinary cortisol excretion (r = 0.11, P < 0.001), as well as with the total urinary excretion of glucocorticoid metabolites (r = 0.32, P < 0.001). This correlation was not present between copeptin and urinary cortisone excretion (r = 0.01, P = 0.76). There was also a positive correlation between copeptin and the estimated enzymatic activity (r = 0.15, P < 0.001).
Association between copeptin and metabolic outcomes using mixed models
As expected, T2D was positively associated with copeptin levels in crude analyses as well as after full adjustment ( Table 3) . As for MetS, the association was lost after adjustment for age and sex.
As there was an interaction between 11β-HSD2 activity and copeptin for the association with HOMA-IR, we conducted stratified analyses for all adjustment models and presented the results of the regression by 11β-HSD2 activity levels ( Table 4) . We saw an association between insulin resistance (= HOMA-IR) and copeptin both in low and high activity strata, but this association was stronger in the presence of high apparent 11β-HSD2 activity as compared to a reduced 11β-HSD2 activity. We observed that in all models. In Fig. 1 , we depicted the predicted probability of insulin resistance at each quartiles of log-transformed copeptin adjusted for age, center and sex, separately for high-and low 11β-HSD2 activity. Although both associations remain positive, we see graphically how the slope of the association is different (P interaction = 0.057). Table 4 Association of insulin resistance with serum copeptin levels by 11β-hydroxysteroid dehydrogenase type 2 activity strata, and, association of insulin resistance and fasting glucose with serum copeptin levels by age strata P interaction between copeptin and age < 0.001 in relation to HOMA-IR P interaction between copeptin and age < 0.001 in relation to fasting glucose P interaction between copeptin and 11β-HSD2 activity = 0.057 in relation to HOMA-IR a Estimates are regression coefficients. Mixed multivariate linear and logistic regression models were built Outcomes 11β-HSD2 activity strata We also presented in Table 4 the association of copeptin with HOMA-IR and fasting glucose stratified by age, as there was a significant interaction between age and copeptin for both outcomes (P interaction < 0.001 for both). HOMA-IR and fasting glucose were associated positively with copeptin levels only in the oldest group, not in the youngest one, in all adjusted models. When we additionally adjusted for sex hormones (urinary testosterone and estradiol excretion), similar patterns were found.
Sensitivity analyses in which daytime urine flow rate and 24 h urinary creatinine excretion were added as covariates lead to very similar results and did not alter the conclusions (see Supplementary Table 2 ). Further sensitivity analyses restricted to untreated participants or adding CRP and eGFR as covariates did not change the results (data not shown).
Discussion
We corroborate the association of insulin resistance with copeptin in a large population-based study. Both crosssectional and prospective studies [1] [2] [3] [4] [5] 9] have shown an association between higher levels of copeptin and features of metabolic disorders. This association was identified in obese men [1] , in hypertensive subjects [5] and in the general population in cross-sectional studies [3] . Prospective longitudinal studies have also shown the association of elevated copeptin levels with the later development of abdominal obesity, diabetes [4, 9] and microalbuminuria [2] .
The observation that insulin resistance, or fasting glucose, is associated with copeptin levels only in the eldest participants is novel. One possible explanation is that older participants may be more susceptible to alterations in the hypothalamic-neurohypophysal-vasopressin axis than the younger ones. We know that there is a dysfunction in this pathway as a result of aging, which leads to multiple abnormalities in different physiological systems [29] . Levels of AVP are frequently chronically elevated in the elderly, which can worsen some pathologies such as congestive heart failure, diabetes, hypertension [29] . It has been recently shown that high plasma copeptin was associated with reduced insulin sensitivity and increased risk for prediabetes and type 2 diabetes in a community-based cohort [9] . There was also evidence of an association of AVP genetic variants with incident hyperglycemia in men, but not in women, supporting a causal role for vasopressin in T2D, in particular when vasopressin levels are high [9] . Our results are in line with these findings and confirm that the association of copeptin with insulin resistance and fasting glucose is mainly present in the oldest participants.
In the present study, we investigated whether the apparent 11β-HSD2 activity modulates the association between insulin resistance and copeptin. The 11β-HSD2 enzyme, which is primarily expressed in aldosterone-sensitive tissues (such as kidney, placenta, colon and salivary glands), converts cortisol to inactive cortisone; thus alteration in this enzymatic activity might affect tissue availability of circulating levels of glucocorticoids, thereby potentially influencing the development of insulin resistance. We found that, If daytime HSD11B2 activity is low in the highest 11β-HSD2 activity strata, insulin resistance was strongly positively associated with copeptin levels. High apparent 11β-HSD2 activity suggests accelerated catabolism of cortisol. These results are compatible with the hypothesis that insulin resistance may be linked to AVP via increased cortisol production. Indeed, we found a significant positive association of serum copeptin with daytime urinary cortisol excretion. This higher enzymatic activity could be a protective mechanism in order to eliminate the excess of cortisol. Experimental studies have shown that AVP stimulates 11β-HSD2 expression in mineralocorticosteroid target cells [11] . However, in our study, plasma copeptin levels were lower when apparent 11β-HSD2 activity, assessed using daytime urinary corticosteroid ratio, was high, which is not in line with the experimental studies. Indeed, we could have expected that, according to the experimental data, copeptin levels would be higher when the enzymatic activity was higher. Additional studies, both epidemiological and experimental, are needed to corroborate these results and further elucidate the mechanisms underlying these findings.
Strengths of the present study include the measure of urinary steroids excretion, which is very unique in populationbased epidemiological studies. By consequence, we were able to estimate the apparent 11β-HSD2 enzyme activity and to study its potential influence on the copeptin-metabolic syndrome relationship in the general adult population, which is novel. We also had data on socioeconomic status, lifestyle patterns (physical activity levels, fruits and vegetables consumption, tobacco and alcohol consumption), so we have accounted for a large variety of factors that could affect the association between copeptin and insulin resistance.
This study has some limitations too. The cross-sectional design of the study impedes to draw conclusions about causality, but longitudinal human studies have shown that vasopressin elevation precedes diabetes and insulin resistance [2, 9, 30] . Additionally, using these observational data, we can only capture a marginal effect that likely combines both type 1 and type 2 11β-HSD enzymatic activities [31] . In fact, using the urinary F/E ratio we are estimating the 11β-HSD2 enzymatic activity, which is not a direct measure. In addition, we do not know the temporal relationship between the increase in apparent 11β-HSD2 enzymatic activity, the increase in insulin resistance and the increase in plasma copeptin levels. Therefore, reverse causality cannot be excluded. Experimental studies are needed to further elucidate the underlying mechanisms. Finally, we had few cases of Metabolic Syndrome and T2D in our population, so the power of our analyses was limited for these outcomes.
In conclusion, our results help getting further insight into the copeptin-metabolic syndrome relationship in the general adult population. We have shown an effect modification of age and apparent 11β-HSD2 activity on the association of insulin resistance with copeptin. Insulin resistance was positively associated with copeptin levels in older participants, but not in young people, and this relationship was particularly steep and positive whenever apparent 11β-HSD2 activity is elevated. This latter result is in line with the idea that AVP increases cortisol production and catabolism in the general adult population. Further studies are warranted to understand the underlying mechanisms of these findings and to investigate potential pharmacological ways to counterbalance this association in order to prevent the development of metabolic disorders.
